Previous 10 |
Enochian developing ENOB-HV-01 an autologous cell therapy as a potentially curative treatment for HIV LOS ANGELES, March 07, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (Nasdaq: ENOB), a biotechnology company developing potentially curative and preventative genetically modified...
Thinly traded micro cap Enochian Biosciences ( OTCQB:ENOB +19.2% ) is up on more than double normal volume, albeit on turnover of only 90K shares, ahead of today's investor event . More news on: Enochian Biosciences Inc., Healthcare stocks news, Stocks on the move, Read more .....
CORAL GABLES, FL / ACCESSWIRE / February 1, 2019 / The healthcare stock market's success is largely dependent on the fact that, as the global population increases, more people will fall prey to illnesses and ailments, and in turn, these individuals will need access to qualitative, effectiv...
Gainers: TMSR Holding Company (NASDAQ: TMSR ) +223%. Integrated Media Technology (NASDAQ: IMTE ) +104% . Titan Pharmaceuticals (NASDAQ: TTNP ) +34%. Professional Diversity Network (NASDAQ: IPDN ) +30% . Continental Materials (NYSEMKT: CUO ) +29% . Gravity (NASDAQ: GRVY ) ...
News, Short Squeeze, Breakout and More Instantly...
Enochian Biosciences Inc. Company Name:
ENOB Stock Symbol:
NASDAQ Market:
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the “Annual Meeting”), which was sched...